The First Biomedical Supply Chain Industrialization Service Center in Western China Established in Chengdu Tianfu International Biotown

The 2nd China International Import Expo, which just concluded, has built a remarkable global open platform. In Chengdu, which is 2,000 kilometers away, it is also actively planning the same thing, trying to show open, innovative and inclusive urban character under the global spotlight.

On November 15th, Chengdu International Conference For Biomedical Supply Chain 2019 (referred to as “Conference”) was held in Chengdu. The conference was hosted by The People’s Government of Chengdu Municipality and China National Pharmaceutical Group Co., Ltd., and the theme is to accelerate the establishment of a new hub for international supply chain in Chengdu.” More than 100 companies including the world’s top 500 pharmaceutical companies, and representatives of domestic leading pharmaceutical companies attended the Conference, such as Novartis, Merck (MSD), and Takeda Pharmaceutical.

As a top-end high-end conference in the industry, the conference attracted global biomedical supply chain industry experts, multinational corporations and international organizations to gather together to create a global biomedical supply chain hub, three aspects from “seeing new opportunities in the international pharmaceutical supply chain”, “Chengdu has created a new exploration and exploration of the new hub of biomedical supply chain”, and the “International Biomedical Supply Chain Service System Guarantee” has been discussed, in order to interpret doubts, share experiences and look forward to the future.

Building a Global Supply Chain Hub Chengdu, Tianfu International Biotown Supply Chain Service Co., Ltd. was Established

It is learned that the conference attracted guests from well-known domestic and foreign companies such as Jeter Bellin, Beaufort, Puxi, Novo Nordisk, Fessen Yuskebi, Takeda Pharmaceutical, and GlaxoSmithKline. Experts from countries and regions such as the United States, the United Kingdom, the Netherlands, Belgium, and Singapore participated.

What opportunities will there be in the future international biomedical supply chain? What strategic thinking do they have? In the forum that morning, many experts shared their insights.

In the morning forum, economist, Zhou Tianyong, former vice president of the International Strategy Institute of the Central Party School, Thomas Porstner, president of the German Pharmaceutical Wholesalers Association, and Zhou Xiaoyuan, director of the Supervision and Evaluation Division of the National Health and Health Commission, from international and domestic The macro-environment perspective shares the topic of the policy and market environment of the pharmaceutical supply chain. Mr. Chen Zhiyi, Executive Director of Allergan, Vice President of Sinopharm Holding Co., Ltd., Cai Buyong, Chairman of Southwest China National Pharmaceutical Corporation, Nuth Mony, Head of Secretariat of the Ministry of Health of Cambodia, and He Xun, Deputy Director of Sichuan Medical Products Administration, and other industry practitioners And the head of the regulatory department conducted a round-table dialogue on Chengdu’s pioneering and innovative exploration and practice of building a new hub for the international biomedical supply chain.

It is worth mentioning that at the meeting of the day, Chengdu Tianfu International Biotown Supply Chain Service Co., Ltd. announced the unveiling of its establishment. The company is a joint venture established by Sinopharm Southwest Company and Chengdu Tianfu International Biotown Investment Development Co., Ltd. It is a specialized pharmaceutical import agency and will rely on the specialization advantages of Sinopharm Group to provide professional services for international and domestic pharmaceutical companies to choose Chengdu Customs and to build a global biomedical supply chain service center.

According to the company, it plans a total construction area of 13,000 square meters, and the warehouse planning area is covered with a whole cool storage area, planning three-dimensional refrigerator, flat refrigerator, freezer, constant temperature special library, double temperature inspection area, and other functional areas which can realize the storage of about 2,000 medicine trays and about 30,000 cases of medicines at the same time. Part of the bonded warehouse area can realize the whole process of cold chain medicine from transportation to inspection, storage and storage, and ensure the safe storage of medicines.

It is reported that as a provincial subsidiary established by the pharmaceutical group in Sichuan, Sinopharm Group Southwest Pharmaceutical Co., Ltd. has strictly controlled quality management for many years, and strives to create a professional three-party logistics system and cold chain distribution system, advanced management experience and strict quality management system. Helping the rapid development of new companies and promoting the integration of the biomedical industry into the high-end and value chain core of the global industrial chain.

On the day of the inauguration, Chengdu Tianfu International Biotown Supply Chain Service Co., Ltd. concentrated on signing a cooperation agreement with Chengdu International Railway Port Investment Development (Group) Co., Ltd. and Sichuan Airport Group Co., Ltd. to build a port drug inspection and storage base. The three parties will cooperate in an all-round way to jointly help Chengdu to create a new hub for the international biomedical supply chain.

Regional Resource Complementation, Biomedical Supply Chain May Go to the Railway Era

Chen Wei, dean of the Zhangjiang Platform Economic Research Institute in Shanghai Pudong New Area, who is attending the Conference, believes that the global biomedical supply chain center established by Chengdu Tianfu International Biotown can make full use of the advantages of Chengdu’s air and rail transportation and utilize the international and domestic “Two Markets”. “Two kinds of Resources”, attracting the Asia-Pacific supply headquarters of famous Chinese and foreign pharmaceutical companies, attracting high-end innovative resources such as talents, innovation achievements and new models of industrial development, new formats and new technologies.

“In the past, 80% of were by air and 20% by sea. Now we have rail transport, which saves a lot of money compared to air transport.” In Chen Wei’s view, Chengdu’s global biomedical supply chain service center is not only air transported by dual airports. In addition to the advantages, the railway advantage is also a key factor. “If Chengdu has built a bio-medical supply chain, it can become the first stop for the import of new drugs from the Belt and Road. Although it is difficult, once the supply chain is really opened, maybe the supply chain of biomedicine will move from the air transport era to the railway era.”

The construction of the International Biomedical Supply Chain Center in Chengdu is also optimistic, in the opinion of Thomas Porstner, President of the German Pharmaceutical Wholesalers Association.

As an expert in regulatory and GxP, market access and licensing issues, in his view, Chengdu’s current efforts to build an international biomedical supply chain center has given Germany and even European pharmaceutical companies an additional option to enter the Chinese market. “Drugs have very strict standards for temperature and other storage conditions during the transportation process. Therefore, we are most concerned about whether medicines shipped from Europe to China can maintain their efficacy. In this regard, Chengdu is actively promoting The cold chain logistics will play an important role.”

In this regard, Chengdu Tianfu International Biotown has had early moves. According to people from Chengdu Tianfu International Biotown, the 15,000 square meters cold chain logistics warehouse in Biotown is accelerating construction, of which 2000 square meters is a bonded cold chain logistics warehouse. After being fully completed, it will be ranked first grade in the domestic cold chain logistics facility base and service capacity.

It is learned that Chengdu Tianfu International Biotown includes the “four-chain one-community one-system” industrial ecosystem including the supply chain (ie, industry chain, innovation chain, supply chain, financial chain, living livable international community, professional and precise service system), with talent gathering as the core element, this is the core competitiveness of Biotown.

“Chengdu Tianfu International Biotown is an international biomedical park built by Chengdu Municipality. It has advanced planning, perfect industrial function layout, and perfect living facilities. It is currently developing towards new urban goals.” People from Hitgen said that this is also their choice. The reason for the project to settle in Biotown.

It is also learned that Chengdu Tianfu International Biotown was planned on March 14, 2016. After three years of development, a total of 127 projects have been introduced, with a total investment of more than 100 billion yuan. Among them, there are 5 Nobel Prize teams, 4 national academician teams, and 51 high-level talent teams. The goal is to become a world-renowned bio-industry Innovation and Entreprenuership talent habitat, a world-class bio-industry innovation and intellectual capital international life-healthy town, integrated into the global industry chain high-end and value chain core innovation practice area.

Media Contact
Company Name: Am-News
Contact Person: JANE
Email: Send Email
Country: United States